Ignet

Gene Information

Gene symbol: KIF2C

Gene name: kinesin family member 2C

HGNC ID: 6393

Synonyms: MCAK

Related Genes

#	Gene Symbol	Number of hits
1	CD8A	1 hits
2	HLA-A	1 hits
3	IL7	1 hits

Related Sentences

#	PMID	Sentence
1	21165574	Identification of HLA-A0201/-A2402-restricted CTL epitope-peptides derived from a novel cancer/testis antigen, MCAK, and induction of a specific antitumor immune response.
2	21165574	To evaluate the feasibility of developing cancer immunotherapy using MCAK peptides, we studied HLA-A0201 and 2402 as targets for CTLs in the context of HLA class I molecules.
3	21165574	By using a peptide with a sequence of AINPELLQL (amino acid positions 63-71 in MCAK, HLA-A0201) and FFEIYNGKL (amino acid positions 401-409 in MCAK, HLA-A2402), CTL responses could be induced from unseparated PBMCs by stimulation of freshly isolated, peptide-pulsed PBMCs as antigen-presenting cells (APCs) and also by using interleukin-7 and keyhole limpet hemocyanin in primary culture.
4	21165574	The induced CTLs could lyse HLA-A-0201/2402 colon and gastric cancer cells expressing MCAK, as well as the peptide-pulsed target cells, in an HLA class l, and CD8 restricted manner.
5	21165574	The identification of the MCAK/HLA-A0201 and 2402 peptides suggests the possibility of designing peptide-based immunotherapeutic approaches that might prove effective in treating patients with MCAK-positive cancer.
6	21165574	Identification of HLA-A0201/-A2402-restricted CTL epitope-peptides derived from a novel cancer/testis antigen, MCAK, and induction of a specific antitumor immune response.
7	21165574	To evaluate the feasibility of developing cancer immunotherapy using MCAK peptides, we studied HLA-A0201 and 2402 as targets for CTLs in the context of HLA class I molecules.
8	21165574	By using a peptide with a sequence of AINPELLQL (amino acid positions 63-71 in MCAK, HLA-A0201) and FFEIYNGKL (amino acid positions 401-409 in MCAK, HLA-A2402), CTL responses could be induced from unseparated PBMCs by stimulation of freshly isolated, peptide-pulsed PBMCs as antigen-presenting cells (APCs) and also by using interleukin-7 and keyhole limpet hemocyanin in primary culture.
9	21165574	The induced CTLs could lyse HLA-A-0201/2402 colon and gastric cancer cells expressing MCAK, as well as the peptide-pulsed target cells, in an HLA class l, and CD8 restricted manner.
10	21165574	The identification of the MCAK/HLA-A0201 and 2402 peptides suggests the possibility of designing peptide-based immunotherapeutic approaches that might prove effective in treating patients with MCAK-positive cancer.
11	21165574	Identification of HLA-A0201/-A2402-restricted CTL epitope-peptides derived from a novel cancer/testis antigen, MCAK, and induction of a specific antitumor immune response.
12	21165574	To evaluate the feasibility of developing cancer immunotherapy using MCAK peptides, we studied HLA-A0201 and 2402 as targets for CTLs in the context of HLA class I molecules.
13	21165574	By using a peptide with a sequence of AINPELLQL (amino acid positions 63-71 in MCAK, HLA-A0201) and FFEIYNGKL (amino acid positions 401-409 in MCAK, HLA-A2402), CTL responses could be induced from unseparated PBMCs by stimulation of freshly isolated, peptide-pulsed PBMCs as antigen-presenting cells (APCs) and also by using interleukin-7 and keyhole limpet hemocyanin in primary culture.
14	21165574	The induced CTLs could lyse HLA-A-0201/2402 colon and gastric cancer cells expressing MCAK, as well as the peptide-pulsed target cells, in an HLA class l, and CD8 restricted manner.
15	21165574	The identification of the MCAK/HLA-A0201 and 2402 peptides suggests the possibility of designing peptide-based immunotherapeutic approaches that might prove effective in treating patients with MCAK-positive cancer.
16	21165574	Identification of HLA-A0201/-A2402-restricted CTL epitope-peptides derived from a novel cancer/testis antigen, MCAK, and induction of a specific antitumor immune response.
17	21165574	To evaluate the feasibility of developing cancer immunotherapy using MCAK peptides, we studied HLA-A0201 and 2402 as targets for CTLs in the context of HLA class I molecules.
18	21165574	By using a peptide with a sequence of AINPELLQL (amino acid positions 63-71 in MCAK, HLA-A0201) and FFEIYNGKL (amino acid positions 401-409 in MCAK, HLA-A2402), CTL responses could be induced from unseparated PBMCs by stimulation of freshly isolated, peptide-pulsed PBMCs as antigen-presenting cells (APCs) and also by using interleukin-7 and keyhole limpet hemocyanin in primary culture.
19	21165574	The induced CTLs could lyse HLA-A-0201/2402 colon and gastric cancer cells expressing MCAK, as well as the peptide-pulsed target cells, in an HLA class l, and CD8 restricted manner.
20	21165574	The identification of the MCAK/HLA-A0201 and 2402 peptides suggests the possibility of designing peptide-based immunotherapeutic approaches that might prove effective in treating patients with MCAK-positive cancer.
21	21165574	Identification of HLA-A0201/-A2402-restricted CTL epitope-peptides derived from a novel cancer/testis antigen, MCAK, and induction of a specific antitumor immune response.
22	21165574	To evaluate the feasibility of developing cancer immunotherapy using MCAK peptides, we studied HLA-A0201 and 2402 as targets for CTLs in the context of HLA class I molecules.
23	21165574	By using a peptide with a sequence of AINPELLQL (amino acid positions 63-71 in MCAK, HLA-A0201) and FFEIYNGKL (amino acid positions 401-409 in MCAK, HLA-A2402), CTL responses could be induced from unseparated PBMCs by stimulation of freshly isolated, peptide-pulsed PBMCs as antigen-presenting cells (APCs) and also by using interleukin-7 and keyhole limpet hemocyanin in primary culture.
24	21165574	The induced CTLs could lyse HLA-A-0201/2402 colon and gastric cancer cells expressing MCAK, as well as the peptide-pulsed target cells, in an HLA class l, and CD8 restricted manner.
25	21165574	The identification of the MCAK/HLA-A0201 and 2402 peptides suggests the possibility of designing peptide-based immunotherapeutic approaches that might prove effective in treating patients with MCAK-positive cancer.